What's the most attractive weight-loss stock right now? We asked Seeking Alpha analysts Edmund Ingham, Stephen Ayers and Oneil Trader for their picks. Read more here.

Actinogen Medical Limited announces that the World Health Organization (WHO) has granted the nonproprietary name of 'emestedastat' to Actinogen for its Xanamem®/UE2343 once-a-day small molecule in ...

The international consulting firm Clarivate makes its bet among the novelties ready for the medicine cabinet this year: three ...

Advocates say microdosing reduces costs and side effects while maintaining weight loss, then can help with weight maintenance. The approach is especially popular among telemedicine physicians, who ...

New research suggests that Ozempic and similar weight loss medications have the potential to be as big a game changer in ...

All lines have been placed on mute to prevent any background noise. There will be a question-and-answer session at the ...

The question of putative mechanisms of action continues to haunt psychopharmacology. Put simply, we know these drugs work, but we have very little idea how. We make guesses based on the ...

We read with interest the article by Marie Lund and colleagues published in The Lancet Oncology investigating the association ...

Physician–scientists at the University of Utah's John A. Moran Eye Center have published an investigatory review of nine patients who experienced vision complications while taking popular semaglutide ...

Eli Lilly's tirzepatide has been shown to significantly cut cardiovascular risks in patients with obesity and a form of heart failure with few treatment options, in another big win for the GLP-1 ...

In line with that, our review highlights the well-accepted mechanisms of action and resistance to the therapy and discusses the progress that has been made toward successfully overcoming this ...

The full lineup of late-breaking clinical science to be presented at THT 2025: Technology and Heart Failure Therapeutics is now available online. Organized by the Cardiovascular Research Foundation® ...